A high ratio of chromogranin A to synaptin/synaptophysin is a common feature of brains in Alzheimer and Pick disease  by Weiler, Rosa et al.
Vo lume 263, number  2, 337-339 FEBS 08364 Apri l  1990 
A high ratio of chromogranin A to synaptin/synaptophysin is a common 
feature of brains in Alzheimer and Pick disease 
Rosa Weiler, Hans Lassmann +, Peter Fischer +, Kur t  Jellinger ° and Hans Winkler 
Department of Pharmacology, University of lnnsbruck, Peter Mayr-Strafle la, A-6020 Innsbruck, +Institute of Brain Research, 
Austrian Academy of Sciences and Neurological Institute, University of Vienna nd °Ludwig Boltzmann Institute for Clinical 
Neurobiology, Lainz Hospital, A-1090 Vienna, Austria 
Received 7 March  1990 
Chromogranin A and synaptin/synaptophysin were characterized by immunological methods in human autopsy brain tissue from patients with 
Alzheimer's and Pick's disease. In immunoblots there was no qualitative difference between the antigens in control and diseased brain, but signifi- 
cant quantitative differences were found. In all Alzheimer cases there was a significantly lower level of synaptin/synaptophysin, whereas chromo- 
granin A was higher in 4 out of 5 cases and in all cases relative to synaptin/synaptophysin. An analogous finding was obtained for Pick's disease. 
Immunohistologically a consistent staining of neuritic plaques for chromogranin A, but not for secretogranin I! was found in Alzheimer cases. 
In Pick's disease the characteristic Pick bodies showed an analogous pecific immunostaining. 
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1. INTRODUCTION 
Chromogranin A and secretogranin 1I (chromo- 
granin C) are proteins present in endocrine [1,2] and in 
large dense core vesicles of brain [3]. Synaptin/synap- 
tophysin [4] is found in high concentrations in synaptic 
vesicles [5-7], but also in large dense core vesicles and 
endocrine vesicles [5,8,9]. Recently it has been reported 
that a monoclonal antibody against chromogranin A 
recognizes the characteristic plaques of Alzheimer's 
disease [10] indicating the presence of chromogranin 
immunoreactive material in these lesions. We report 
now for Alzheimer's and Pick's disease that a high 
chromogranin A/synaptin(synaptophysin) ratio is a 
common characteristic for these two brain diseases 
leading to dementia. 
2. MATERIALS AND METHODS 
The study was performed on human autopsy brain tissue from the 
Vienna Prospective Longitudinal Study on Dementia [1 II. It included 
21 cases of Alzheimer's disease (age: 59-88), 3 cases of Pick's disease 
(age: 66-75), 4 cases of mixed dementia (multiple cerebral infarcts 
together with lesions of Alzheimer's type, age: 77-92), and 5 non- 
demented control cases (age 57-91). 
lmmunostaining for chromogranin A and secretogranin 1I was per- 
formed on paraffin sections. The sections were deparaffinized, 
unspecific binding was blocked with 10070 fetal calf serum. Polyclonal 
rabbit primary antisera were used in dilutions of 1:300. Bound an- 
tibody was visualized with an alkaline-phosphatase/anti-alkaline 
phosphatase t chnique [12]. As controls the primary antiserum was 
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omitted or replaced by normal rabbit serum in identical dilutions. 
The techniques of Bielschowsky silver impregnation and im- 
munocytochemistry for tau were described in detail earlier [13]. 
For immunoblotting with a polyclonal antiserum [14] against 
human chromogranin (dilution 1:200) heat stable extracts (cor- 
responding to 1 g wet tissue) of lyophilized brain tissue [15] were 
used. For synaptin/synaptopbysin (polyclonal antiserum against rat 
synaptin/synaptophysin kindly provided by R. Jahn, Munich, FRG) 
lyophilized tissue samples (corresponding to 25 mg wet tissue) were 
dissolved irectly in electrophoresis sample buffer. 
3. RESULTS 
In the normal human neocortex and hippocampus 
the distribution of chromogranin A-like immunoreac- 
tivity was identical to that described previously in sheep 
brain [3]. Within neurons, chromogranin A was found 
in a granular distribution in the cytoplasm of nerve cells 
(results not shown). No chromogranin A-like im- 
munoreactivity was found in the white matter. 
Secretogranin II reactivity was identical to that of 
chromogranin A, although the overall intensity of the 
immune reaction was lower. In Alzheimer's disease, in 
addition to the pattern found in normal brains 
numerous enile plaques contained chromogranin A- 
reactive, dystrophic neurites. A detailed quantitative 
analysis of these plaques in comparison with those 
stained by Bielschowsky's ilver technique revealed 
that, dependent upon the case, 2-100°70 (50 +_ 5, n = 
24) of plaques in the tissue visualized by the modified 
Bielschowsky technique contained chromogranin A like 
immunoreactivity. This highly divergent incidence was 
due to the fact, that chromogranin A was exclusively 
present in plaques with a neuritic component. Diffuse 
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Fig. 1. Immunoblots of tissue samples of control and Alzheimer 
brain, lmmunostaining (anti-A: anti chromogranin A; anti-Syn: anti 
synaptin/synaptophysin) of samples from temporal cortex of brains 
from a control patient (C: 57 M), from two Alzheimer cases (AI: 75 
M; A2:79 F) and from a case with morbus Pick (P) are shown. A 
quantitative comparison of the various samples is not possible from 
this figure since the film obtained from the labelled blot was 
overexposed toshow as many bands as possible in a way suitable for 
printing. PG-A: proteoglycan-chromogranin A; AM: heat stable 
extract from human adrenal medulla. 
( 'ear ly ' )  plaques did not reveal chromogranin  A im- 
munoreact iv ity.  In P ick 's  disease all P ick bodies (as 
determined by staining adjacent sections with either 
Bielschowsky silver impregnat ion or immunocyto-  
chemistry for tau) were intensively stained with anti- 
bodies against chromogranin  A. In both Alzheimer 's  
and P ick 's  disease secretogranin II like immunoreac-  
Table I 
Levels of chromogranin A and synaptin/synaptophysin 
Subject Age Sex Ch-A Syn Ch-A/Syn 
(years) 
Controls 57 M 145 104.4 1.4 
91 M 48 94.1 0.5 
54 M 79.4 93 0.9 
67 M 127.5 108.4 1.2 
Mean +_ SE 99.9_+22.2 99.9_+3.8 1.0___0.2 
Alzheimer 77 M 301 69 4.4 
73 F 272 87.2 3.1 
72 F 200 74.5 2.7 
75 M 281 65.1 4.3 
79 F 78 19.1 4.1 
Mean + SE 226.4_+40.8* 63-+ 11,6" 3.7-+0.3** 
Pick 75 F 396.7 36.8 _+ 8.7 10.8 
Heat stable extracts of brains from non-demented controls and from 
cases of Alzheimer's and Pick's disease were subjected to quantitative 
immunoblotting [15]. Four controls and 5 Alzheimer cases were 
available, For Pick's disease only one brain was analyzed; the results 
of several measurements (n = 2 for Ch-A; n = 4 for syn) for different 
brain samples are presented. Statistical differences: * P < 0.05; 
• * P <0.001. 
tivity was exclusively present in granular distr ibut ion in 
the cytoplasm of  nerve cells. Pick bodies and plaque 
neurites were negative for secretogranin II. These im- 
munohistochemical  results demonstrate that chromo- 
granin A immunoreact iv i ty  is consistently found both 
in Alzheimer plaques and Pick bodies; however, this 
method does not allow any statements on the propert ies 
and relative quantity of  the immunoreact ive material .  
In order to define this immunoreact ive material  in 
molecular  terms immunoblots  were performed.  Pre- 
vious studies (see [1]) have establ ished that in extracts 
of  immediately processed endocrine and brain tissues 
antisera gainst chromogranin  A react with the propro-  
tein chromogranin  A and several smaller proteins 
which are formed within the storage vesicles by endo- 
genous processing. For  tissues not immediately pro- 
cessed a further breakdown leading to smaller proteins 
becomes apparent  [16]. For  human brain, as shown in 
Fig. 1, the proprote in  chromogranin  A can still be 
demonstrated (A in Fig. 1). In addit ion a faster moving 
breakdown product  (A1 in Fig. 1) is present in varying 
relative amounts.  A slower moving band (PG-A in 
Fig. 1) has been previously [17] identif ied as the pro- 
teoglycan form of  chromogranin  A,  which can be 
found consistently in brain tissue, e.g. of  rat [1,18]. As 
shown in Fig. 1 there is no significant qualitative dif- 
ference between the chromogranin  A-reactive bands in 
control  or diseased brains. The apparent  prominence of  
the proteoglycan-chromogranin  A in P ick 's  brains is 
due to the fact that higher levels of  total chromogranin 
were present in these samples. Synapt in /synaptophys in  
(see Fig. 1) could also be demonstrated in human brain. 
For  secretogranin II our method was not sensitive 
enough. 
The quantitat ive valuation of  chromogranin  A and 
synapt in /synaptophys in  levels is shown in Table I, A 
consistent f inding for all Alzheimer cases was the lower 
level of  synapt in /synaptophys in;  o  the other hand in 
4 out of  5 Alzheimer cases the chromogranin  A level 
was remarkably  elevated. In a fifth case the 
chromogran in  A level was below control,  but the 
chromogran in  A/synapt in(synaptophys in)  ratio was 
still high. It seems likely that in this case a considerable 
cell loss has reduced a previously elevated 
chromogran in  A level below control.  Only one brain of  
P ick 's  disease was available for immunoblott ing;  
nevertheless, everal samples were analyzed and a very 
high level of  chromogranin A and of  the chromogranin  
A /synapt in(synaptophys in)  ratio was detected. 
4. D ISCUSSION 
Synapt in /synaptophys in  is a protein found in high 
concentrat ions in synaptic vesicles [5-7],  and in lower 
concentrat ion in large dense core vesicles and in en- 
docr ine vesicles like chromaff in  granules [5,8,9]. Its 
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consistent low levels in Alzheimer's (which is in agree- 
ment with immunohistochemical data [19,20]) and 
Pick's brains can simply be an expression of neuronal 
and synaptic loss occurring in these diseases, but a 
specific loss of  synaptic vesicles should also be con- 
sidered. On the other hand, chromogranin A levels are 
increased. This protein is found in endocrine vesicles 
and large dense core vesicles of  brain and is secreted 
together with other constituents of  these vesicles by ex- 
ocytosis. This property is shared with neuropeptides 
[1]. For some neuropeptides, an immunohistochemical 
staining of  Alzheimer plaques has been observed [21], 
but we are unaware of  a report describing high levels of  
any of  these peptides in brain. In fact reduced levels 
have been reported (see also [22]) for neuropeptide Y 
[23] and somatostatin [24]. In addition we have not 
found immunostaining of  Alzheimer plaques or of Pick 
bodies with an antiserum against secretogranin II which 
at least in chromaffin granules is colocalized with 
chromogranin A [25]. Therefore our results on 
chromogranin A levels seem quite specific for this 
secretory protein. Unfortunately the function of  this 
protein is still not very well defined, although peptides 
derived from it (e.g. pancreastatin) have been shown to 
inhibit the secretion of  hormones [26,27]. 
Elevated levels of  chromogranin A in diseased brain 
might be a consequence of  an increased synthesis or 
decreased secretion or breakdown. Our present study 
does not yet allow us to state whether chromogranin A 
is only accumulating in the typical lesions or is elevated 
in all neurons. This can only be elucidated in further 
studies including mRNA-measurements.  In this context 
it is interesting to note that one report has claimed that 
in adrenal medulla of Alzheimer patients large vacuoles 
with electron dense content (protein?) have been found 
[28]. The adrenal medulla contains a high concentra- 
tion of chromogranin A [1]. Does this suggest that 
peripheral organs also contain more chromogranin as it 
has recently been shown for the amyloid fl protein 
precursor [29]? In any case we consider our results im- 
portant for the following reasons: we have found 
chromogranin A immunostaining both in Alzheimer 
plaques and Pick bodies. The immunoreactive material 
was identified as chromogranin A. In both diseases the 
brain contains increased levels of this secretory protein 
found in large dense core vesicles whereas synap- 
t in/synaptophysin levels are low. These data for 
chromogranin A appear specific, since other secretory 
constituents of  large dense core vesicles (secretogranin 
II, neuropeptides) behave differently. Thus for these 
two diseases leading to dementia but with significantly 
differing pathohistology a high chromogranin 
A/synaptin(synaptophysin) ratio is a common and 
specific denominator. These data might also become 
relevant for diagnostic purposes: does the cerebrospinal 
fluid of Alzheimer and Pick patients contain higher 
levels of  chromogranin A or of  peptides derived from 
it? 
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